Rifaximina en enfermedad diverticular sintomática no complicada. Revisión sistemática de la literatura

Vista sencilla de ítem
dc.contributor.advisorOtero Regino, William Albertospa
dc.contributor.advisorEstrada Orozco, Kellyspa
dc.contributor.authorBastidas Riascos, Melissa del Rosariospa
dc.date.accessioned2022-02-16T17:11:49Z
dc.date.available2022-02-16T17:11:49Z
dc.date.issued2021
dc.descriptionilustraciones, gráficas, tablasspa
dc.description.abstractRifaximina en enfermedad diverticular sintomática no complicada. Revisión sistemática de la literatura Introducción: La rifaximina es un antibiótico que inhibe la síntesis del ARN bacteriano y se ha propuesto en el tratamiento de enfermedad diverticular sintomática no complicada (EDSNC), pero hay controversia sobre su utilidad. Objetivo: Determinar la efectividad y seguridad de la rifaximina frente a otras intervenciones o no intervención en la mejoría de los síntomas de pacientes con EDSNC. Materiales y métodos: Investigamos en todas las bases de datos hasta Julio 2021 para identificar experimentos clínicos, otros estudios de intervención, cohortes o casos y controles que evaluaran la efectividad y seguridad de la rifaximina frente a otras intervenciones o no intervención en la mejoría de los síntomas de pacientes con EDSNC. La calidad metodológica de los estudios incluidos se evaluó de acuerdo al tipo de diseño. Se realizó síntesis cualitativa. Resultados: se tamizaron 1489 referencias. Se revisaron 18 referencias en texto completo, de las cuales se excluyeron siete. 11 estudios cumplieron criterios de inclusión y exclusión. En los ECA (ensayos clínicos) existió mejoría en el score global sintomático a 14+/-2 días p<0.005, 6 meses (p<0.001), 12 meses (p<0.001), 24 meses (p<0.001) con diferencias estadísticamente significativa. En el estudio cuasiexperimetal y en los estudios observacionales también existió reducción significativa a los 3 meses (p<0.001) 6 meses p (0,0001), 8 años (p<0.001). Los efectos adversos, fueron menor al 1%, y no tienen diferencias significativas (NS) en relación al grupo comparador. Rifaximina no tiene utilidad en la prevención de complicaciones (NS). La heterogeneidad clínica y metodológica debido a las diferentes mediciones de los desenlaces y definiciones del score sintomático, no permite establecer medidas combinadas del efecto. Conclusiones: Rifaximina es mejor que la fibra (glucomanano solo), superior a placebo en mejoria de los síntomas. Se requieren más estudios para confirmar estos hallazgos. Se recomienda realizar ECA bien diseñados para establecer el impacto de la rifaximina en EDSNC. (Texto tomado de la fuente).spa
dc.description.abstractRifaximin in uncomplicated symptomatic diverticular disease. Systematic review of the literature Introduction: Rifaximin is an antibiotic that inhibits bacterial RNA synthesis and has been proposed for the treatment of uncomplicated symptomatic diverticular disease (NCSD), but there is controversy about its usefulness. Objective: To determine the effectiveness and safety of rifaximin compared to other interventions or no intervention in improving the symptoms of patients with EDSNC. Materials and methods: We searched all databases up to July 2021 to identify clinical trials, other intervention studies, cohorts, or cases and controls that evaluated the effectiveness and safety of rifaximin versus other interventions or no intervention in improving symptoms. symptoms of patients with EDSNC. The methodological quality of the included studies was assessed according to the type of design. Qualitative synthesis was performed. Results: 1489 references were screened. Eighteen full-text references were reviewed, of which seven were excluded. 11 studies met inclusion and exclusion criteria. In the RCTs (clinical trials) there was an improvement in the global symptomatic score at 14+/-2 days p<0.005, 6 months (p<0.001), 12 months (p<0.001), 24 months (p<0.001) with differences statistically significant. In the quasi-experimental study and in the observational studies there was also a significant reduction at 3 months (p<0.001), 6 months p (0.0001), 8 years (p<0.001). Adverse effects were less than 1%, and have no significant differences (NS) in relation to the comparator group. Rifaximin has no utility in the prevention of complications (NS). The clinical and methodological heterogeneity due to the different measurements of the outcomes and definitions of the symptom score, does not allow to establish combined measures of the effect. Conclusions: Rifaximin is better than fiber (glucomannan alone), superior to placebo in symptom improvement. Further studies are required to confirm these findings. Well-designed RCTs are recommended to establish the impact of rifaximin on EDSNC.eng
dc.description.degreelevelEspecialidades Médicasspa
dc.description.degreenameEspecialista en Gastroenterologíaspa
dc.description.notesIncluye anexos
dc.format.extentxi, 55, 7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/80996
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Medicina Internaspa
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Medicina - Especialidad en Gastroenterologíaspa
dc.relation.indexedBiremespa
dc.relation.references1. Tursi A, Papa A, Danese S. Review article: The pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Alimentary Pharmacology and Therapeutics. 2015;42(6):664–84.spa
dc.relation.references2. Binda GA, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R, et al. Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Techniques in Coloproctology [Internet]. 2018;22(8):597–604. Available from: http://dx.doi.org/10.1007/s10151-018-1840-zspa
dc.relation.references3. Tursi A, Scarpignato C, Strate LL, Lanas A, Kruis W, Lahat A, et al. Colonic diverticular disease. Nature Reviews Disease Primers [Internet]. 2020;6(1):1–23. Available from: http://dx.doi.org/10.1038/s41572-020-0153-5spa
dc.relation.references4. Everhart JE, Ruhl CE. Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas. Gastroenterology [Internet]. 2009 [cited 2021 Jun 24];136(4):1134–44. Available from: https://pubmed.ncbi.nlm.nih.gov/19245868/spa
dc.relation.references5. Tursi A. New physiopathological and therapeutic approaches to diverticular disease: an update. Expert opinion on pharmacotherapy [Internet]. 2014 [cited 2022 Jan 4];15(7):1005–17. Available from: https://pubmed.ncbi.nlm.nih.gov/24684571/spa
dc.relation.references6. Binda GA, Mataloni F, Bruzzone M, Carabotti M, Cirocchi R, Nascimbeni R, et al. Trends in hospital admission for acute diverticulitis in Italy from 2008 to 2015. Techniques in Coloproctology [Internet]. 2018 Aug 1 [cited 2021 Jun 24];22(8):597–604. Available from: https://pubmed.ncbi.nlm.nih.gov/30196450/spa
dc.relation.references7. Etzioni DA, MacK TM, Beart RW, Kaiser AM. Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment. Annals of Surgery [Internet]. 2009 Feb [cited 2021 Jun 25];249(2):210–7. Available from: https://pubmed.ncbi.nlm.nih.gov/19212172/spa
dc.relation.references8. Warner E, Crighton EJ, Moineddin R, Mamdani M, Upshur R. Fourteen-year study of hospital admissions for diverticular disease in Ontario. Canadian Journal of Gastroenterology [Internet]. 2007 [cited 2021 Jun 25];21(2):97–9. Available from: https://pubmed.ncbi.nlm.nih.gov/17299613/spa
dc.relation.references9. Kang JY, Hoare J, Tinto A, Subramanian S, Ellis C, Majeed A, et al. Diverticular disease of the colon - On the rise: A study of hospital admissions in England between 1989/1990 and 1999/2000. Alimentary Pharmacology and Therapeutics [Internet]. 2003 May 1 [cited 2021 Jun 24];17(9):1189–95. Available from: https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2036.2003.01551.xspa
dc.relation.references10. Heise CP. Epidemiology and pathogenesis of diverticular disease. Journal of Gastrointestinal Surgery [Internet]. 2008 Aug [cited 2021 Jun 24];12(8):1309–11. Available from: https://pubmed.ncbi.nlm.nih.gov/18278535/spa
dc.relation.references11. Burkitt DP, Walker ARP, Painter NS. EFFECT OF DIETARY FIBRE ON STOOLS AND TRANSIT-TIMES, AND ITS ROLE IN THE CAUSATION OF DISEASE [Internet]. Vol. 300, The Lancet. Lancet; 1972 [cited 2021 Jun 24]. p. 1408–11. Available from: https://pubmed.ncbi.nlm.nih.gov/4118696/spa
dc.relation.references12. Lanas A, Abad-Baroja D, Lanas-Gimeno A. Progress and challenges in the management of diverticular disease: which treatment? [Internet]. Vol. 11, Therapeutic Advances in Gastroenterology. SAGE Publications Ltd; 2018 [cited 2021 Jun 24]. Available from: /pmc/articles/PMC6056793/spa
dc.relation.references13. Crowe FL, Appleby PN, Allen NE, Key TJ. Diet and risk of diverticular disease in Oxford cohort of European Prospective Investigation into Cancer and Nutrition (EPIC): Prospective study of British vegetarians and non-vegetarians. BMJ (Online). 2011 Jul 30;343(7817).spa
dc.relation.references14. Epidemiology of noninfective intestinal diseases in various ethnic groups in South Africa - PubMed [Internet]. [cited 2021 Jun 24]. Available from: https://pubmed.ncbi.nlm.nih.gov/447496/spa
dc.relation.references15. Guías clínicas de diagnóstico y tratamiento de la enfermedad diverticular del colon. Etiología, fisiopatología, epidemiología: en México y el mundo | Revista de Gastroenterología de México [Internet]. [cited 2021 Jun 24]. Available from: http://www.revistagastroenterologiamexico.org//es-guias-clinicas-diagnostico-tratamiento-enfermedad-articulo-X0375090608497984spa
dc.relation.references16. Commane DM, Arasaradnam RP, Mills S, Mathers JC, Bradburn M. Diet, ageing and genetic factors in the pathogenesis of diverticular disease [Internet]. Vol. 15, World Journal of Gastroenterology. Baishideng Publishing Group Co; 2009 [cited 2021 Jun 24]. p. 2479–88. Available from: https://pubmed.ncbi.nlm.nih.gov/19468998/spa
dc.relation.references17. Stumpf M, Cao W, Klinge U, Klosterhalfen B, Kasperk R, Schumpelick V. Increased distribution of collagen type III and reduced expression of matrix metalloproteinase 1 in patients with diverticular disease. International Journal of Colorectal Disease [Internet]. 2001 [cited 2021 Jun 24];16(5):271–5. Available from: https://pubmed.ncbi.nlm.nih.gov/11686522/spa
dc.relation.references18. Wess L, Eastwood MA, Wess TJ, Busuttil A, Miller A. Cross linking of collagen is increased in colonic diverticulosis. Gut [Internet]. 1995 [cited 2021 Jun 25];37(1):91–4. Available from: https://pubmed.ncbi.nlm.nih.gov/7672689/spa
dc.relation.references19. Horgan AF, McConnell EJ, Wolff BG, The S, Paterson C. Atypical diverticular disease: Surgical results. Diseases of the Colon and Rectum [Internet]. 2001 [cited 2021 Jun 25];44(9):1315–8. Available from: https://pubmed.ncbi.nlm.nih.gov/11584207/spa
dc.relation.references20. Clemens CHM, Samsom M, Roelofs J, van Berge Henegouwen GP, Smout AJPM. Colorectal visceral perception in diverticular disease. Gut [Internet]. 2004 May [cited 2021 Jun 24];53(5):717–22. Available from: https://pubmed.ncbi.nlm.nih.gov/15082591/spa
dc.relation.references21. Humes DJ, Simpson J, Smith J, Sutton P, Zaitoun A, Bush D, et al. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterology and Motility [Internet]. 2012 Apr [cited 2021 Jun 24];24(4). Available from: https://pubmed.ncbi.nlm.nih.gov/22276853/spa
dc.relation.references22. Simpson J, Sundler F, Humes DJ, Jenkins D, Scholefield JH, Spiller RC. Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms. Neurogastroenterology and Motility [Internet]. 2009 Aug [cited 2021 Jun 24];21(8). Available from: https://pubmed.ncbi.nlm.nih.gov/19453515/spa
dc.relation.references23. Bassotti G, Sietchiping-Nzepa F, de Roberto G, Chistolini F, Morelli A. Colonic regular contractile frequency patterns in irritable bowel syndrome: The “spastic colon” revisited. European Journal of Gastroenterology and Hepatology [Internet]. 2004 Jun [cited 2021 Jun 24];16(6):613–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15167165/spa
dc.relation.references24. Bassotti G, Villanacci V, Bernardini N, Dore MP. Diverticular disease of the colon neuromuscular function abnormalities. In: Journal of Clinical Gastroenterology [Internet]. Lippincott Williams and Wilkins; 2016 [cited 2021 Jun 24]. p. S6–8. Available from: https://pubmed.ncbi.nlm.nih.gov/27622368/spa
dc.relation.references25. Barbara G, Scaioli E, Barbaro MR, Biagi E, Laghi L, Cremon C, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut [Internet]. 2017 Jul 1 [cited 2021 Jun 24];66(7):1252–61. Available from: https://pubmed.ncbi.nlm.nih.gov/27618836/spa
dc.relation.references26. C Papi 1, A Ciaco, M Koch LC. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group. Ital J Gastroenterol. 1992;24(8):452–6.spa
dc.relation.references27. Strate LL, Erichsen R, Baron JA, Mortensen J, Pedersen JK, Riis AH, et al. Heritability and familial aggregation of diverticular disease: A population-based study of twins and siblings. Gastroenterology [Internet]. 2013 [cited 2021 Jun 24];144(4). Available from: https://pubmed.ncbi.nlm.nih.gov/23313967/spa
dc.relation.references28. Santin BJ, Prasad V, Caniano DA. Colonic diverticulitis in adolescents: An index case and associated syndromes. Pediatric Surgery International [Internet]. 2009 [cited 2021 Jun 24];25(10):901–5. Available from: https://pubmed.ncbi.nlm.nih.gov/19711089/spa
dc.relation.references29. Bläker H, Funke B, Hausser I, Hackert T, Schirmacher P, Autschbach F. Pathology of the large intestine in patients with vascular type Ehlers-Danlos syndrome. Virchows Archiv [Internet]. 2007 Jun [cited 2021 Jun 24];450(6):713–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17487505/spa
dc.relation.references30. Vennix S, Morton DG, Hahnloser D, Lange JF, Bemelman WA. Systematic review of evidence and consensus on diverticulitis: An analysis of national and international guidelines [Internet]. Vol. 16, Colorectal Disease. Blackwell Publishing Ltd; 2014 [cited 2021 Jun 24]. p. 866–78. Available from: https://pubmed.ncbi.nlm.nih.gov/24801825/spa
dc.relation.references31. van de Wall BJM, Draaisma WA, van Iersel JJ, van der Kaaij R, Consten ECJ, Broeders IAMJ. Dietary restrictions for acute diverticulitis: Evidence-based or expert opinion? International Journal of Colorectal Disease [Internet]. 2013 Sep [cited 2021 Jun 24];28(9):1287–93. Available from: https://pubmed.ncbi.nlm.nih.gov/23604409/spa
dc.relation.references32. Spiller R. Diverticular disease and IBS overlapping or misunderstanding? In: Journal of Clinical Gastroenterology [Internet]. Lippincott Williams and Wilkins; 2016 [cited 2021 Jun 24]. p. S29–32. Available from: https://pubmed.ncbi.nlm.nih.gov/27622357/spa
dc.relation.references33. Cuomo R, Barbara G, Andreozzi P, Bassotti G, Casetti T, Grassini M, et al. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. European Journal of Clinical Investigation [Internet]. 2013 Nov [cited 2021 Jun 24];43(11):1147–55. Available from: https://pubmed.ncbi.nlm.nih.gov/23992370/spa
dc.relation.references34. Maconi G. Diagnosis of symptomatic uncomplicated diverticular disease and the role of rifaximin in management. Acta Biomedica. 2017;88(1):25–32.spa
dc.relation.references35. Flor N, Maconi G, Cornalba G, Pickhardt PJ. The current role of radiologic and endoscopic imaging in the diagnosis and follow-up of colonic diverticular disease [Internet]. Vol. 207, American Journal of Roentgenology. American Roentgen Ray Society; 2016 [cited 2021 Jun 24]. p. 15–24. Available from: https://pubmed.ncbi.nlm.nih.gov/27082846/spa
dc.relation.references36. Cuomo R, Barbara G, Pace F, Annese V, Bassotti G, Binda GA, et al. Italian consensus conference for colonic diverticulosis and diverticular disease. Vol. 2, United European Gastroenterology Journal. 2014. 413–442.spa
dc.relation.references37. Enfermedad diverticular: mitos y realidades [Internet]. [cited 2021 Jun 24]. Available from: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872017000200009spa
dc.relation.references38. Dragoni G, Innocenti T, Galli A. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? Digestive Diseases [Internet]. 2021 [cited 2021 Jun 24];39(3):190–203. Available from: www.karger.com/ddispa
dc.relation.references39. Tursi A, Brandimarte G, Elisei W, Giorgetti GM, Inchingolo CD, Aiello F. Faecal calprotectin in colonic diverticular disease: A case-control study. International Journal of Colorectal Disease [Internet]. 2009 [cited 2021 Jun 24];24(1):49–55. Available from: https://pubmed.ncbi.nlm.nih.gov/18941760/spa
dc.relation.references40. Tursi A, Elisei W, Picchio M, Giorgetti GM, Brandimarte G. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: A comparison with fecal calprotectin in clinical setting. Journal of Clinical Gastroenterology [Internet]. 2015 Mar 13 [cited 2021 Jun 24];49(3):218–21. Available from: https://pubmed.ncbi.nlm.nih.gov/24583746/spa
dc.relation.references41. Chabok A, Påhlman L, Hjern F, Haapaniemi S, Smedh K. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. British Journal of Surgery [Internet]. 2012 Apr [cited 2021 Jun 24];99(4):532–9. Available from: https://pubmed.ncbi.nlm.nih.gov/22290281/spa
dc.relation.references42. Isacson D, Smedh K, Nikberg M, Chabok A. Long-term follow-up of the AVOD randomized trial of antibiotic avoidance in uncomplicated diverticulitis. British Journal of Surgery [Internet]. 2019 Oct 1 [cited 2021 Jun 24];106(11):1542–8. Available from: https://pubmed.ncbi.nlm.nih.gov/31386199/spa
dc.relation.references43. Schultz JK, Azhar N, Binda GA, Barbara G, Biondo S, Boermeester MA, et al. European Society of Coloproctology: guidelines for the management of diverticular disease of the colon. Colorectal Disease [Internet]. 2020 Sep 1 [cited 2021 Jun 24];22(S2):5–28. Available from: https://pubmed.ncbi.nlm.nih.gov/32638537/spa
dc.relation.references44. Stallinger S, Eller N, Högenauer C. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wiener Klinische Wochenschrift. 2014 Jan;126(1–2):9–14.spa
dc.relation.references45. INVIMA. Ministerio de Salud y de la Protección Social - Instituto Nacional de Vigilancia de Medicamentos y Alimentos - Invima. 2015;10. Available from: http://farmacovigilancia.invima.gov.co:8082/Consultas/consultas/consreg_encabcum.jsp%5Cnspa
dc.relation.references46. Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, et al. Meta-analysis: Long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Alimentary Pharmacology and Therapeutics. 2011 Apr;33(8):902–10.spa
dc.relation.references47. Corazza GR, di Stefano M, Scarpignato C. Treatment of functional bowel disorders: Is there room for antibiotics? Digestion. 2006;73(SUPPL. 1):38–46.spa
dc.relation.references48. Colecchia A, Vestito A, Pasqui F, Mazzella G, Roda E, Pistoia F, et al. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease CLINICAL RESEARCH. World J Gastroenterol [Internet]. 2007;13(2):264–9. Available from: www.wjgnet.comspa
dc.relation.references49. Zullo A, Hassan C, Maconi G, Manes G, Tammaro G, de Francesco V, et al. Cyclic antibiotic therapy for diverticular disease: A critical reappraisal. Journal of Gastrointestinal and Liver Diseases. 2010;19(3):295–302.spa
dc.relation.references50. PAPI C, CIACO A, KOCH M, CAPURSO L. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double‐blind placebo‐controlled trial [Internet]. Vol. 9, Alimentary Pharmacology & Therapeutics. Aliment Pharmacol Ther; 1995 [cited 2021 Jun 6]. p. 33–9. Available from: https://pubmed.ncbi.nlm.nih.gov/7766741/spa
dc.relation.references51. Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. International Journal of Colorectal Disease. 2003;18(1):55–62.spa
dc.relation.references52. D’Incà R, Pomerri F, Vettorato MG, Dal Pont E, di Leo V, Ferronato A, et al. Interaction between rifaximin and dietary fibre in patients with diverticular disease. Alimentary Pharmacology and Therapeutics [Internet]. 2007 Apr [cited 2021 Jun 6];25(7):771–9. Available from: https://pubmed.ncbi.nlm.nih.gov/17373915/spa
dc.relation.references53. Pietrzak AM, Banasiewicz T, Skoczylas K, Dziki A, Szczepkowski M. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease. Polish Journal of Surgery. 2020;92(2):22–8.spa
dc.relation.references54. de Bastiani R, Sanna G, Bertolusso L, Casella G, de Polo M, Zamparella M, et al. General practitioners’ management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic. European Review for Medical and Pharmacological Sciences. 2021;25(1):423–30.spa
dc.relation.references55. di Mario F, Miraglia C, Cambiè G, Violi A, Nouvenne A, Franceschi M, et al. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. Journal of Investigative Medicine. 2019;67(4):767–70.spa
dc.relation.references56. Lanas A, Ponce J, Bignamini A, Mearin F. One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: A proof-of-concept study. Digestive and Liver Disease. 2013;45(2):104–9.spa
dc.relation.references57. Tursi A. Diverticulosis today: Unfashionable and still under-researched. Therapeutic Advances in Gastroenterology. 2016;9(2):213–28.spa
dc.relation.references58. Scarpignato C, Barbara G, Lanas A, Strate LL. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therapeutic Advances in Gastroenterology. 2018;11:1–21.spa
dc.relation.references59. Strate LL, Modi R, Cohen E, Spiegel BMR. Diverticular disease as a chronic illness: Evolving epidemiologic and clinical insights. American Journal of Gastroenterology [Internet]. 2012;107(10):1486–93. Available from: http://dx.doi.org/10.1038/ajg.2012.194spa
dc.relation.references60. Hawkins AT, Wise PE, Chan T, Lee JT, Glyn T, Wood V, et al. Diverticulitis: An Update From the Age Old Paradigm. Current Problems in Surgery [Internet]. 2020;57(10):100862. Available from: https://doi.org/10.1016/j.cpsurg.2020.100862spa
dc.relation.references61. Riddle MS, Dupont HL, Connor BA. ACG clinical guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults. American Journal of Gastroenterology [Internet]. 2016;111(5):602–22. Available from: http://dx.doi.org/10.1038/ajg.2016.126spa
dc.relation.references62. Kvasnovsky CL, Leong LEX, Choo JM, Abell GCJ, Papagrigoriadis S, Bruce KD, et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: A pilot study. European Journal of Gastroenterology and Hepatology. 2018;30(1):107–12.spa
dc.relation.references63. Kurpad A v., Shetty PS. Effects of antimicrobial therapy on faecal bulking. Gut. 1986;27(1):55–8.spa
dc.relation.references64. Latella G, Scarpignato C. Rifaximin in the management of colonic diverticular disease. Expert Review of Gastroenterology and Hepatology. 2009;3(6):585–98.spa
dc.relation.references65. Cuomo R, Barbara G, Annibale B. Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease [Internet]. 2017;49(6):595–603. Available from: http://dx.doi.org/10.1016/j.dld.2017.01.164spa
dc.relation.references66. Nice Guidelines. Diverticular disease: diagnosis and management. NICE guideline Published: 27 November 2019. 2019;85(November).spa
dc.relation.references67. Sartelli M, Weber DG, Kluger Y, Ansaloni L, Coccolini F, Abu-Zidan F, et al. 2020 update of the WSES guidelines for the management of acute colonic diverticulitis in the emergency setting. World Journal of Emergency Surgery. 2020;15(1):1–18.spa
dc.relation.references68. Bianchi M, Festa V, Moretti A, Ciaco A, Mangone M, Tornatore V, et al. Meta-analysis: Long-term therapy with rifaximin in the management of uncomplicated diverticular disease. Alimentary Pharmacology and Therapeutics [Internet]. 2011 Apr [cited 2021 Jun 24];33(8):902–10. Available from: https://pubmed.ncbi.nlm.nih.gov/21366632/spa
dc.relation.references69. Tursi A, Brandimarte G, Daffinà R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Digestive and Liver Disease. 2002;34(7):510–5.spa
dc.relation.references70. Julian Higgins1 JT. Cochrane Handbook for Systematic Reviews of Interventions.spa
dc.relation.references71. Urrutia G, Bonfill X. Declaración PRISMA. Vol. 135, Medicina Clínica. 2010. p. 507–11.spa
dc.relation.references72. Https://gradepro.org/. GRADEpro.spa
dc.relation.references73. Comparato G, Fanigliulo L, Aragona G, Cavestro GM, Cavallaro LG, Leandro G, et al. Quality of life in uncomplicated symptomatic diverticular disease: Is it another good reason for treatment? Digestive Diseases. 2007;25(3):252–9.spa
dc.relation.references74. Campanini A, de Conto U, Cavasin F, Bastiani F, Camarotto A, Gardini L, et al. A primary-care interventional model on the diverticular disease: Searching for the optimal therapeutic schedule. In: Journal of Clinical Gastroenterology. Lippincott Williams and Wilkins; 2016. p. S93–6.spa
dc.relation.references75. Pietrzak AM, Dziki A, Banasiewicz T, Reguła J. Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: A retrospective study. Przeglad Gastroenterologiczny. 2019;14(1):69–78.spa
dc.relation.references76. Lue A, Laredo V, Lanas A. Medical treatment of diverticular disease: Antibiotics. In: Journal of Clinical Gastroenterology. Lippincott Williams and Wilkins; 2016. p. S57–9.spa
dc.relation.references77. Marcello Picchio 1, Walter Elisei 2 AT 3. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials. J Gastrointestin Liver Dis. 2018;27(3):291–7.spa
dc.relation.references78. Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World Journal of Gastroenterology. 2017;23(25):4491–9.spa
dc.relation.references79. Saavedra-Perez D, Curbelo-Peña Y, Sampson-Davila J, Albertos S, Serrano A, Ibañez L, et al. Management of symptomatic uncomplicated diverticular colon disease: A systematic review of diagnosis and treatment. Vol. 44, Gastroenterologia y Hepatologia. Ediciones Doyma, S.L.; 2021. p. 497–518.spa
dc.relation.references80. Salem TA, Molloy RG, O’Dwyer PJ. Prospective, five-year follow-up study of patients with symptomatic uncomplicated diverticular disease. Diseases of the Colon and Rectum. 2007 Sep;50(9):1460–4.spa
dc.relation.references81. Picchio M, Elisei W, Tursi A. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials [Internet]. Vol. 27, Journal of Gastrointestinal and Liver Diseases. Romanian Society of Gastroenterology; 2018 [cited 2021 Jun 6]. p. 291–7. Available from: https://pubmed.ncbi.nlm.nih.gov/30240473/spa
dc.relation.references82. Brandimarte G, Tursi A. WWW. MEDSCI MONIT.COM Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease [Internet]. Available from: http://www.MedSciMonit.com/pub/vol_10/no_5/4390.pdfspa
dc.relation.references83. Pistoia M, et al; does rifaximin prevent complications of diverticular disease? a retrospective study. Eur Rev Med Pharmacol Sci. 2004;8(6): 283-7.spa
dc.relation.references84. Moniuszko A, Rydzewska G. The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic: A “real-life” study. Przeglad Gastroenterologiczny. 2017;12(2):145–51.spa
dc.relation.references85. Conte D, Orlando S. Rifaximin plus fibre versus fibre alone in preventing diverticulitis recurrence: A (problematic) trial to tackle an epidemiologically relevant problem. Vol. 45, Digestive and Liver Disease. 2013. p. 102–3.spa
dc.relation.references86. Pietrzak AM, Banasiewicz T, Skoczylas K, Dziki A, Szczepkowski M. Combined therapy: rifaximin-α and arabinogalactan with lactoferrin combination effectively prevents recurrences of symptomatic uncomplicated diverticular disease. Polish Journal of Surgery. 2020 Apr 7;92(2):22–8.spa
dc.relation.references87. Banasiewicz T, Paszkowski J, Borejsza-Wysocki M, Bobkiewicz A, Pietrzak A, Szczepkowski M, et al. The effectiveness of prophylactic combination therapy (rifaximin alfa + arabinogalactan and lactoferrin prebiotic) on gastrointestinal function in patients with diagnosed symptomatic uncomplicated diverticular disease. Polski Przeglad Chirurgiczny/ Polish Journal of Surgery. 2019;91(4):1–8.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseAtribución-SinDerivadas 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.decsDivertículospa
dc.subject.decsDiverticulumeng
dc.subject.decsSystematic Revieweng
dc.subject.decsRevisión Sistemáticaspa
dc.subject.decsRifaximineng
dc.subject.decsRifaximinaspa
dc.subject.proposalRifaximinaspa
dc.subject.proposalRifaximineng
dc.subject.proposalEnfermedad diverticular no complicadaspa
dc.subject.proposalUncomplicated diverticular diseaseeng
dc.subject.proposalRifaximineeng
dc.subject.proposalRifaximinspa
dc.titleRifaximina en enfermedad diverticular sintomática no complicada. Revisión sistemática de la literaturaspa
dc.title.translatedRifaximin in symptomatic uncomplicated diverticular disease. Systematic review of the literatureeng
dc.typeTrabajo de grado - Especialidad Médicaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentBibliotecariosspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentGrupos comunitariosspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
dcterms.audience.professionaldevelopmentMaestrosspa
dcterms.audience.professionaldevelopmentMedios de comunicaciónspa
dcterms.audience.professionaldevelopmentPersonal de apoyo escolarspa
dcterms.audience.professionaldevelopmentPúblico generalspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1085286671.2021.pdf
Tamaño:
757.87 KB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Especialidad en Gastroenterología
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialidad en Gastroenterología